Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Profound MedicalPROF -6.68%70 Price-to-Tangible-Book is 4.54 as of Aug. 09, 2026, which is 1% above its 10-year median of 4.50. GuruFocus rates PROF with a GF Score™ of 70/100 and a GF Value™ of $14.49 (Possible Value Trap). The stock has 1 warning sign investors should review. Among 707 Medical Devices & Instruments companies, Profound Medical ranks worse than 68.46% on this metric.
The historical rank and industry rank for Profound Medical's Price-to-Tangible-Book or its related term are showing as below:
PROF'
s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.54 Med: 4.5 Max: 19.41
Current: 4.6
During the past 12 years, Profound Medical's highest Price to Tangible Book Ratio was 19.41. The lowest was 1.54. And the median was 4.50.
PROF's Price-to-Tangible-Book is ranked worse than 68.46% of 707
companies
in the Medical Devices & Instruments industry
Industry Median: 2.64
vs PROF: 4.60
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Profound Medical Price-to-Tangible-Book Related Terms
Profound Medical Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for Profound Medical's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PROF vs ABT, SYK, MDT: Price-to-Tangible-Book Comparison
For the Medical Devices subindustry, Profound Medical's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Profound Medical Price-to-Tangible-Book vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Profound Medical's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Profound Medical's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Profound Medical (PROF) has a Price-to-Tangible-Book of 4.54 as of Aug. 09, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Profound Medical and its competitors. This is near median its historical median of 4.50. Over the past decade, Profound Medical's Price-to-Tangible-Book has ranged from 1.54 to 19.41. According to the industry distribution chart, Profound Medical ranks #484 out of 707 companies in the Medical Devices & Instruments industry, placing it in the top 68.5%.
Is Profound Medical's Price-to-Tangible-Book too high?
Profound Medical's current Price-to-Tangible-Book of 4.54 is near median its 10-year median of 4.50. Over the past 10 years, this metric has ranged from a low of 1.54 to a high of 19.41. The Medical Devices & Instruments industry median Price-to-Tangible-Book is 2.64. Profound Medical's value of 4.54 is 72% above this industry median. Based on the distribution chart, Profound Medical ranks #484 out of 707 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Profound Medical has a GF Score™ of 70/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Profound Medical's Price-to-Tangible-Book compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Profound Medical ranks #484 out of 707 companies for Price-to-Tangible-Book. This places Profound Medical in the lower half of its industry. The industry median Price-to-Tangible-Book is 2.64. Profound Medical's value of 4.54 is 72% above this benchmark. Historically, Profound Medical's own Price-to-Tangible-Book has ranged from 1.54 to 19.41 over the past decade. While the company's 10-year median is 4.50 vs. the industry median of 2.64, Profound Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Medical Devices & Instruments company?
The median Price-to-Tangible-Book among Medical Devices & Instruments companies is 2.64, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Profound Medical's current Price-to-Tangible-Book of 4.54 is 72% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Profound Medical and its competitors. For the Medical Devices & Instruments industry, the median Price-to-Tangible-Book is 2.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Profound Medical's current Price-to-Tangible-Book is 4.54, which is near median its own 10-year median of 4.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Profound Medical stock overvalued right now?
Based on GuruFocus' analysis, Profound Medical (PROF) is currently considered Possible Value Trap. The stock's GF Value™ is $14.49, compared to a current price of $7.41 — trading 48.9% below its estimated fair value. The current Price-to-Tangible-Book is 4.54, which is near median its 10-year median of 4.50 and 72% above the Medical Devices & Instruments industry median of 2.64. Profound Medical's overall GF Score™ is 70/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For Profound Medical (PROF), the current Price-to-Tangible-Book is 4.54 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Profound Medical (PROF) Overvalued in 2026?
Based on GuruFocus' analysis, Profound Medical stock appears to be undervalued.
The current stock price of $7.41 is trading 48.9% below its estimated GF Value™ of $14.49.
GuruFocus considers Profound Medical to be Possible Value Trap.
Key valuation signals for PROF:
Price-to-Tangible-Book: 4.54 (near median its 10-year median of 4.50)
GF Value™: $14.49 vs. price of $7.41 (48.9% below fair value)
Industry Position: 72% above the Medical Devices & Instruments median (#484 of 707)
No single metric tells the full story. See the PROF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
70GF Score
Get the complete analysis for PROF
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PROF has been successfully added to your 
